This strategic initiative aligns with our vision to enhance precision medicine and capitalize on the significant market opportunities projected by recent industry reports.
Building on over a decade of leadership in array testing, we are now positioning our laboratory to lead the next growth frontier in next-generation sequencing. By leveraging our highly automated robotics labs, we ensure precision diagnostics, rapid turnaround times, and competitive pricing. This investment aligns with the company’s mission to empower our partners with comprehensive genetic data across all fields and make advanced genomic technology more accessible to a broader population.
"Investing in next-generation sequencing is acritical step in our mission to lead the genetic testing industry and support the growing demand for advanced genomic solutions," said Dr. Lior Rauchberger, CEO of Gene by Gene. "With this enhanced capability, we are well-positioned to meet the needs of our clients and partners, drive innovation, and ensure that more people have access to the benefits of personalized medicine."
Recent industry reports indicate that the global NGS market is poised for exponential growth, driven by increasing applications in clinical diagnostics, personalized medicine, and research. Our timely investment aims to leverage this growth, ensuring the company remains at the forefront of technological advancements and market trends while making these advancements more widely available.
"By adopting cutting-edge NGS technology, we are not only enhancing our laboratory capabilities but also expanding our reach into new and emerging markets," added Josh Wittner, President of Gene by Gene. "Our commitment to quality and innovation ensures that we provide our clients with the most accurate and actionable genetic data, ultimately improving patient outcomes and advancing scientific discovery."
Our investment in NGS technology is accompanied by a comprehensive growth strategy, which includes partnerships with leading healthcare providers, research institutions, and biopharmaceutical companies. These collaborations are expected to drive further advancements in genomic research and clinical applications, reinforcing our position as a trusted leader in the genetic testing industry.
The democratization of cutting-edge technology not only enables more patients to benefit from personalized medicine but also acts as a catalyst for further research. By making these tools more accessible, we are fostering an environment where groundbreaking research can thrive, ultimately leading to new discoveries and treatments that can profoundly impact people’s lives and revolutionize medical care.
For more information about our next-generation sequencing capabilities, please visit: https://www.genebygene.com/services/whole-genome-sequencing
Gene by Gene
Company News & Press Releases
Gene By Gene is a world leader in genetic testing services with over 20 years of experience. Our laboratory holds accreditation from multiple agencies, including CAP, CLIA, California Department of Public Health, and AABB. With a cutting-edge laboratory and highly trained team of experts, we are committed to excellence in the field of genetic analysis.
.png)
